ClinicalTrials.gg
Active, not recruitingNCT03837899Updated Sep 29, 2026Results posted

Durvalumab and Tremelimumab for Pediatric Malignancies

A Phase 1/2 interventional study of Durvalumab / Tremelimumab Combination Therapy in Pediatric Cancer, Solid Tumor Pediatric and Hematological Malignancies, sponsored by AstraZeneca. Active, not recruiting at 19 sites in 7 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionHematologic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hematologic Neoplasms
Why
  1. The study's listed conditions name Hematologic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
271st of 658
50 · median 40
Started
2019
with 36 others
Phase 1/2
81 of 821
16 open now
Primary completion
2023-02
later than 27 of 273 live
Registered
435th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 271st largest by enrollment of the 658 interventional ones that give a count, is one of 37 that started in 2019, is one of 81 in phase 1/2, reaches primary completion later than 27 of the 273 other live ones, and was the 435th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

Read the detailed description

This is a first time in pediatrics study primarily designed to evaluate the safety and tolerability of durvalumab and durvalumab in combination with tremelimumab at increasing doses in pediatric patients with advanced solid malignancies and hematological malignancies (including lymphomas) and for whom no standard of care treatments exist. Although treatment efficacy is not a primary objective of this study given its early phase nature, the patients screened for this study have no curative options and this study offers the potential of some benefit.

The study will also characterize the PK of durvalumab and durvalumab in combination with tremelimumab in children and adolescents and explore potential biological activity and immunogenicity by assessing pharmacodynamics, anti drug antibody (ADA) levels, and anti-tumor activity. The results from this trial will form the basis for decisions for potential future pediatric studies

03

Conditions studied

  • Pediatric Cancer
  • Solid Tumor Pediatric
  • Hematological Malignancies

Browse trials for

Keywords

  • Pediatric, solid tumors, hematological malignancies, durvalumab, tremelimumab, immunotherapy
04

In context

Hematologic Neoplasms Reclassified

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

This study's enrollment of 50 is close to the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Max Age =17 years
  • Solid Tumors (except primary central nervous system malignant tumors): Patients must have a histopathologic confirmation of . Patients must have progressed or are to standard therapies, and for whom no standard of care treatments exist
  • Non-Hodgkin's Lymphoma, limited to primary mediastinal B-cell lymphoma and anaplastic large cell lymphoma. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist.
  • Provision of diagnostic tumor sample mandated if available
  • Evaluable disease
  • No prior exposure to immune-mediated therapy
  • Adequate organ and marrow function
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • History of allogeneic organ transplantation (exceptions may be allowed for NHL after discussion with Sponsor). History of bone marrow transplant may be allowed (after discussion with Sponsor).
  • Active or prior documented or inflammatory disorders (exceptions)
  • Uncontrolled intercurrent illness
  • History of primary immunodeficiency
  • Active infection including tuberculosis, , C or
  • Any unresolved toxicity version 5.0 Grade ≥2 from previous anticancer therapy (exceptions)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Durvalumab / Tremelimumab Combination Therapy

    Part 1 (dose finding) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are initially administered at dose level 1 and dose escalated based on results from PK modeling and tolerance to determine the RP2D. Both drugs are administered every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvavalumab for 4 doses, from cycles 2-5. (sarcoma, NB and NHL) Part 2 (dose expansion phase) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are administered at the RP2D, every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvalumab for 4 doses, from cycles 1-4. Tremelimumab may be added for 4 doses at time of progressive disease. Cohorts: solid tumors, sarcomas, NHL restricted to PMBCL and ALCL subtypes)

    Drug: Durvalumab / Tremelimumab Combination Therapy

Interventions

  • DrugDurvalumab / Tremelimumab Combination Therapy

    Drug pages: Durvalumab · Tremelimumab

    Starting dose: durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase.

    Also known as: durvalumab: Imfinzi, MEDI4736, tremelimumab: CP-675,206

07

What researchers measure

Primary outcomes

  1. Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12

  2. Dose-Finding Phase: Minimum Serum Concentration (Cmin) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12

  3. Dose-Finding Phase: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8

  4. Dose-Finding Phase: AUC From Zero to 28 (AUC 0-28) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15

  5. Dose-Finding Phase: Time to Cmax (Tmax) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12

  6. Dose-Finding Phase: Apparent Terminal Elimination Half-life Associated With the Terminal Slope of the Semi-logarithmic Concentration Time Curve (t½λz) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12

  7. Dose-Finding Phase: Dose-Normalized AUC (0-14) (AUC [0-14]/D) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8

  8. Dose-Finding Phase: Dose-Normalized AUC (0-28) (AUC [0-28]/D) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15

  9. Dose-Finding Phase: Dose-Normalized Cmax (Cmax/D) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12

  10. Dose-Finding Phase: Cmax of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5

  11. Dose-Finding Phase: Cmin of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5

  12. Dose-Finding Phase: (AUC 0-14) of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, and Cycle 2 Day 8

  13. Dose-Finding Phase: (AUC 0-28) of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, and Cycle 2 Day 15

  14. Dose-Finding Phase: Tmax of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5

  15. Dose-Finding Phase: T½λz of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5

  16. Dose-Finding Phase: AUC (0-14)/D of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1 and Cycle 2 Day 8

  17. Dose-Finding Phase: AUC (0-28)/D of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, and Cycle 2 Day 15

  18. Dose-Finding Phase: Cmax/D of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5

  19. Dose-Finding Phase: Number of Participants With Adverse Events (AE), Serious AE (SAE), AE Leading to Discontinuation of Durvalumab and Tremelimumab, AE of Special Interest (AESI) or AE of Possible Interest (AEPI) Related to Durvalumab and Tremelimumab

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Some AEs and higher-level terms were considered AESI or AEPIs and this list of categories were provided by the patient safety team.

    Time frame: From Day 1 up to 15 months

  20. Dose-Expansion Phase Only: Objective Response Rate (ORR)

    ORR as per RECIST 1.1 was defined as the percentage of participants with at least 1 investigator-assessed visit response of complete response (CR) or partial response (PR) that was subsequently confirmed on another scan not less than 4 weeks after visit observed response. CR was defined as disappearance of all target lesions (TLs), any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met.

    Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)

  21. Dose-Expansion Phase Only: Duration of Response (DOR)

    Duration of response was the time from the first documentation of CR/PR (which was subsequently confirmed) until the date of documented progression, or death which coincides with the progression free survival (PFS) endpoint. For participants who did not progress following a response, the DOR was censored during the PFS censoring time. It was calculated using Kaplan-Meier technique.

    Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)

  22. Dose-Expansion Phase Only: Best Objective Response (BOR)

    BOR was calculated based on the overall visit responses from each RECIST 1.1 assessment. Categorization of BOR for solid tumors were based on RECIST 1.1 using the following response categories: CR, PR, stable disease (SD), progression of disease (PD), and not evaluable (NE). CR: disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \<10 mm. PR: 30% decrease in the sum of diameters of TLs. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD. PD: \>= 20 % increase in the sum of diameters to TLs and an increase of \>= 5 mm. NE: Only relevant if any of the TLs were not assessed or NE or had a lesion intervention at visit. Non-CR/Non-PD: Persistence of 1+ non-target lesion (s). Non-CR/non-PD was relevant to participants who did not have measurable disease at baseline.

    Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)

  23. Dose-Expansion Phase Only: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who achieved a BOR of unconfirmed CR or PR, respectively, or who had SD. CR was defined as disappearance of all TLs, any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD.

    Time frame: At 16 and 24 Weeks

  24. Dose-Expansion Phase Only: PFS

    PFS as per RECIST 1.1 was defined as the time from the date of first dose of study treatment until the date of objective disease progression or death by any cause in the absence of progression, regardless of whether the participant withdrew from study therapy or received another anti-cancer therapy prior to progression (date of PFS event or censoring - date of first dose + 1). Confidence interval was calculated using Kaplan-Meier technique.

    Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)

  25. Dose-Expansion Phase Only: Overall Survival (OS)

    OS was defined as the time from the date of first dose of study treatment until death due to any cause regardless of whether the patient withdraws from study treatment or received another anti-cancer therapy (i.e date of death or censoring - date of first dose + 1).

    Time frame: From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)

  26. Dose-Expansion Phase Only: Survival Rate at 12 Months and 24 Months

    Survival rates were defined as the Kaplan-Meier estimate of OS at 12 and 24 months.

    Time frame: At 12 and 24 Weeks

Secondary outcomes

  1. Dose-Expansion Phase: Cmax of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12

  2. Dose-Expansion Phase: Cmin of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12

  3. Dose-Expansion Phase: AUC (0-14) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8

  4. Dose-Expansion Phase: AUC (0-28) of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15

  5. Dose-Expansion Phase: Tmax of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12

  6. Dose-Expansion Phase: T½λz of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12

  7. Dose-Expansion Phase: AUC (0-14)/D of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8

  8. Dose-Expansion Phase: AUC (0-28)/D of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15

  9. Dose-Expansion Phase: Cmax/D of Durvalumab

    Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12

  10. Dose-Expansion Phase: Cmax of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4

  11. Dose-Expansion Phase: Cmin of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4

  12. Dose-Expansion Phase: AUC (0-14) of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8

  13. Dose-Expansion Phase: AUC (0-28) of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15

  14. Dose-Expansion Phase: Tmax of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4

  15. Dose-Expansion Phase: T½λz of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4

  16. Dose-Expansion Phase: AUC (0-14)/D of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8

  17. Dose-Expansion Phase: AUC (0-28)/D of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15

  18. Dose-Expansion Phase: Cmax/D of Tremelimumab

    Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

    Time frame: Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4

  19. Dose-Finding Phase: Percentage of Participants Who Developed Detectable Anti-Drug Antibodies (ADAs)

    ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

    Time frame: Pre-infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (durvalumab and tremelimumab), pre-infusion on Cycle 2 Day 1, Cycle 5 Day 1 and Cycle 8 Day 1 for tremelimumab

  20. Dose-Expansion Phase: Percentage of Participants Who Developed Detectable ADAs

    ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. The category includes participants meeting these criteria who are ADA positive at baseline. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category includes participants meeting these criteria who are ADA positive at baseline.

    Time frame: Pre-infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (durvalumab and tremelimumab) and random sample on Cycle 7 Day 1 for tremelimumab

  21. Number of Participants With Individual Antibody Titer Measurement

    Blood samples were planned to be collected for vaccine antibody titer measurements before and after planned routine immunization.

    Time frame: Pre-infusion on Cycle 1 Day 1 and Cycle 4 Day 1 for durvalumab, pre-infusion on Cycle 1 Day 1, pre-infusion on Cycle 3, 4, and 8 Day 1 for tremelimumab (dose-expansion)

  22. Median Percent Change From Baseline of Cluster of Differentiation 4+ (CD4+), CD8+, B Cells, Natural Killer (NK) Cells, and T-cell Activation With Ki67

    Blood samples were collected at indicated timepoints for flow cytometry assessment. Cycle (C) and Day (D). Data collected for the flow cytometry analysis from the participants enrolled in both the dose finding and dose expansion phase were analyzed in the context of the dosing regimen received, to determine any potential differences in the immune response based on the durvalumab dose.

    Time frame: Pre-dose Cycle 1 Day 8, pre-dose Cycle 2 Day 1, Cycle 2 Day 8, pre-dose Cycle 3 Day 1 (Dose-finding); Pre-dose Cycle 1 Day 1, Cycle 1 Day 8, pre-dose Cycle 2 Day 1 (Dose-expansion)

08

Results

Posted Mar 19, 2024

Participant flow

This open-label study was conducted in 2 sequential phases: a dose-finding phase (Phase I), followed by a dose-expansion phase (Phase II) in pediatric participants with advanced solid tumors, including sarcoma. Here, results for data analyzed through data cut-off date (DCO) 20-Apr-2023 have been reported.

Participant flow — Overall Study
MilestoneArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Started711381110
Completed100000
Not completed611381110
Withdrew: Death683787
Withdrew: Moved to post-trial access program010000
Withdrew: Other000002
Withdrew: Lost to follow-up010000
Withdrew: Withdrawal by subject000100
Withdrew: Study specific discontinuation criteria010031

Outcome measures

PrimaryDose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Reported as:
Geometric mean · micrograms/ milliliter (mcg/mL)
Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab
micrograms/ milliliter (mcg/mL)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab363 ± 58.0865 ± 36.0275 ± 135612 ± 34.2
PrimaryDose-Finding Phase: Minimum Serum Concentration (Cmin) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Reported as:
Geometric mean · mcg/mL
Dose-Finding Phase: Minimum Serum Concentration (Cmin) of Durvalumab
mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Minimum Serum Concentration (Cmin) of Durvalumab48.6 ± 104169 ± 28.521.7 ± 34.6118 ± 45.4
PrimaryDose-Finding Phase: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Reported as:
Geometric mean · day*mcg/mL
Dose-Finding Phase: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab
day*mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab2650 ± 61.55660 ± 17.71830 ± 54.73720 ± 46.9
PrimaryDose-Finding Phase: AUC From Zero to 28 (AUC 0-28) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Reported as:
Geometric mean · day*mcg/mL
Dose-Finding Phase: AUC From Zero to 28 (AUC 0-28) of Durvalumab
day*mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: AUC From Zero to 28 (AUC 0-28) of Durvalumab3290 ± 50.18790 ± 13.52500 ± 55.46380 ± 40.1
PrimaryDose-Finding Phase: Time to Cmax (Tmax) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Reported as:
Median · days
Dose-Finding Phase: Time to Cmax (Tmax) of Durvalumab
daysArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Time to Cmax (Tmax) of Durvalumab0.094 (0.09 to 0.10)0.087 (0.00 to 0.14)0.09 (0.09 to 6.94)0.087 (0.08 to 0.09)
PrimaryDose-Finding Phase: Apparent Terminal Elimination Half-life Associated With the Terminal Slope of the Semi-logarithmic Concentration Time Curve (t½λz) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Reported as:
Geometric mean · days
Dose-Finding Phase: Apparent Terminal Elimination Half-life Associated With the Terminal Slope of the Semi-logarithmic Concentration Time Curve (t½λz) of Durvalumab
daysArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Apparent Terminal Elimination Half-life Associated With the Terminal Slope of the Semi-logarithmic Concentration Time Curve (t½λz) of Durvalumab16.7 ± 47.125.3 ± 56.58.26 ± NA15.6 ± 23.3
PrimaryDose-Finding Phase: Dose-Normalized AUC (0-14) (AUC [0-14]/D) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Finding Phase: Dose-Normalized AUC (0-14) (AUC [0-14]/D) of Durvalumab
(day*mcg/mL)/(mg/kg)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Dose-Normalized AUC (0-14) (AUC [0-14]/D) of Durvalumab132 ± 61.5189 ± 17.791.6 ± 54.7124 ± 46.9
PrimaryDose-Finding Phase: Dose-Normalized AUC (0-28) (AUC [0-28]/D) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Finding Phase: Dose-Normalized AUC (0-28) (AUC [0-28]/D) of Durvalumab
(day*mcg/mL)/(mg/kg)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Dose-Normalized AUC (0-28) (AUC [0-28]/D) of Durvalumab164 ± 50.1293 ± 13.5125 ± 55.4213 ± 40.1
PrimaryDose-Finding Phase: Dose-Normalized Cmax (Cmax/D) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12
Reported as:
Geometric mean · (mcg/mL)/(mg/kg)
Dose-Finding Phase: Dose-Normalized Cmax (Cmax/D) of Durvalumab
(mcg/mL)/(mg/kg)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Dose-Normalized Cmax (Cmax/D) of Durvalumab18.1 ± 58.028.8 ± 36.013.7 ± 13520.4 ± 34.2
PrimaryDose-Finding Phase: Cmax of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Reported as:
Geometric mean · mcg/mL
Dose-Finding Phase: Cmax of Tremelimumab
mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Cmax of Tremelimumab19.1 ± 73.324.5 ± 44.739.2 ± 68.823.0 ± 31.7
PrimaryDose-Finding Phase: Cmin of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Reported as:
Geometric mean · mcg/mL
Dose-Finding Phase: Cmin of Tremelimumab
mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Cmin of Tremelimumab3.71 ± 3.753.45 ± 29.2—3.03 ± 50.3
PrimaryDose-Finding Phase: (AUC 0-14) of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, and Cycle 2 Day 8
Reported as:
Geometric mean · day*mcg/mL
Dose-Finding Phase: (AUC 0-14) of Tremelimumab
day*mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: (AUC 0-14) of Tremelimumab127 ± 47.3160 ± 35.6165 ± 7.00149 ± 20.1
PrimaryDose-Finding Phase: (AUC 0-28) of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, and Cycle 2 Day 15
Reported as:
Geometric mean · day*mcg/mL
Dose-Finding Phase: (AUC 0-28) of Tremelimumab
day*mcg/mLArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: (AUC 0-28) of Tremelimumab235 ± 11.2205 ± 22.9—208 ± 14.8
PrimaryDose-Finding Phase: Tmax of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Reported as:
Median · days
Dose-Finding Phase: Tmax of Tremelimumab
daysArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Tmax of Tremelimumab0.046 (0.04 to 0.08)0.051 (0.04 to 0.07)0.040 (0.04 to 0.05)0.046 (0.04 to 0.18)
PrimaryDose-Finding Phase: T½λz of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Reported as:
Geometric mean · days
Dose-Finding Phase: T½λz of Tremelimumab
daysArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: T½λz of Tremelimumab16.8 ± 5.2718.7 ± 20.5—31.6 ± 86.0
PrimaryDose-Finding Phase: AUC (0-14)/D of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC(0-14)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1 and Cycle 2 Day 8
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Finding Phase: AUC (0-14)/D of Tremelimumab
(day*mcg/mL)/(mg/kg)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: AUC (0-14)/D of Tremelimumab127 ± 47.3160 ± 35.6165 ± 7.00149 ± 20.1
PrimaryDose-Finding Phase: AUC (0-28)/D of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC(0-28)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, and Cycle 2 Day 15
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Finding Phase: AUC (0-28)/D of Tremelimumab
(day*mcg/mL)/(mg/kg)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: AUC (0-28)/D of Tremelimumab235 ± 11.2205 ± 22.9—208 ± 14.8
PrimaryDose-Finding Phase: Cmax/D of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5
Reported as:
Geometric mean · (mcg/mL)/(mg/kg)
Dose-Finding Phase: Cmax/D of Tremelimumab
(mcg/mL)/(mg/kg)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Finding Phase: Cmax/D of Tremelimumab19.1 ± 73.324.5 ± 44.739.2 ± 68.823.0 ± 31.7
PrimaryDose-Finding Phase: Number of Participants With Adverse Events (AE), Serious AE (SAE), AE Leading to Discontinuation of Durvalumab and Tremelimumab, AE of Special Interest (AESI) or AE of Possible Interest (AEPI) Related to Durvalumab and Tremelimumab

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Some AEs and higher-level terms were considered AESI or AEPIs and this list of categories were provided by the patient safety team.

Time frame:
From Day 1 up to 15 months
Reported as:
Count of participants · Participants
Dose-Finding Phase: Number of Participants With Adverse Events (AE), Serious AE (SAE), AE Leading to Discontinuation of Durvalumab and Tremelimumab, AE of Special Interest (AESI) or AE of Possible Interest (AEPI) Related to Durvalumab and Tremelimumab
ParticipantsArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Any AE61137
Any SAE1101
AE leading to discontinuation of Durvalumab0000
AE leading to discontinuation of Tremelimumab0100
AESIs or AEPIs related to Durvalumab1402
AESIs or AEPIs related to Tremelimumab0201
PrimaryDose-Expansion Phase Only: Objective Response Rate (ORR)

ORR as per RECIST 1.1 was defined as the percentage of participants with at least 1 investigator-assessed visit response of complete response (CR) or partial response (PR) that was subsequently confirmed on another scan not less than 4 weeks after visit observed response. CR was defined as disappearance of all target lesions (TLs), any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met.

Time frame:
From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Reported as:
Number · percentage of participants
Dose-Expansion Phase Only: Objective Response Rate (ORR)
percentage of participantsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase Only: Objective Response Rate (ORR)011.1
PrimaryDose-Expansion Phase Only: Duration of Response (DOR)

Duration of response was the time from the first documentation of CR/PR (which was subsequently confirmed) until the date of documented progression, or death which coincides with the progression free survival (PFS) endpoint. For participants who did not progress following a response, the DOR was censored during the PFS censoring time. It was calculated using Kaplan-Meier technique.

Time frame:
From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Reported as:
Median · months
Dose-Expansion Phase Only: Duration of Response (DOR)
monthsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase Only: Duration of Response (DOR)—10.8 (10.8 to 10.8)
PrimaryDose-Expansion Phase Only: Best Objective Response (BOR)

BOR was calculated based on the overall visit responses from each RECIST 1.1 assessment. Categorization of BOR for solid tumors were based on RECIST 1.1 using the following response categories: CR, PR, stable disease (SD), progression of disease (PD), and not evaluable (NE). CR: disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \<10 mm. PR: 30% decrease in the sum of diameters of TLs. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD. PD: \>= 20 % increase in the sum of diameters to TLs and an increase of \>= 5 mm. NE: Only relevant if any of the TLs were not assessed or NE or had a lesion intervention at visit. Non-CR/Non-PD: Persistence of 1+ non-target lesion (s). Non-CR/non-PD was relevant to participants who did not have measurable disease at baseline.

Time frame:
From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Reported as:
Count of participants · Participants
Dose-Expansion Phase Only: Best Objective Response (BOR)
ParticipantsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
CR00
PR01
Unconfirmed complete or partial response00
SD >= 7 weeks11
PD97
Not evaluable11
PrimaryDose-Expansion Phase Only: Disease Control Rate (DCR)

DCR was defined as the percentage of participants who achieved a BOR of unconfirmed CR or PR, respectively, or who had SD. CR was defined as disappearance of all TLs, any pathological lymph nodes selected as TLs with reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum of diameters as long as criteria for PD are not met. SD: Neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increased to qualify for PD.

Time frame:
At 16 and 24 Weeks
Reported as:
Number · percentage of participants
Dose-Expansion Phase Only: Disease Control Rate (DCR)
percentage of participantsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Week 169.110.0
Week 249.110.0
PrimaryDose-Expansion Phase Only: PFS

PFS as per RECIST 1.1 was defined as the time from the date of first dose of study treatment until the date of objective disease progression or death by any cause in the absence of progression, regardless of whether the participant withdrew from study therapy or received another anti-cancer therapy prior to progression (date of PFS event or censoring - date of first dose + 1). Confidence interval was calculated using Kaplan-Meier technique.

Time frame:
From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Reported as:
Median · months
Dose-Expansion Phase Only: PFS
monthsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase Only: PFS1.7 (1.58 to 1.91)1.7 (0.89 to 2.76)
PrimaryDose-Expansion Phase Only: Overall Survival (OS)

OS was defined as the time from the date of first dose of study treatment until death due to any cause regardless of whether the patient withdraws from study treatment or received another anti-cancer therapy (i.e date of death or censoring - date of first dose + 1).

Time frame:
From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)
Reported as:
Median · months
Dose-Expansion Phase Only: Overall Survival (OS)
monthsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase Only: Overall Survival (OS)6.6 (2.2 to 15.8)6.9 (3.2 to NA)
PrimaryDose-Expansion Phase Only: Survival Rate at 12 Months and 24 Months

Survival rates were defined as the Kaplan-Meier estimate of OS at 12 and 24 months.

Time frame:
At 12 and 24 Weeks
Reported as:
Number · percentage of participants
Dose-Expansion Phase Only: Survival Rate at 12 Months and 24 Months
percentage of participantsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
12 Months25.6 (6.27 to 51.10)40.0 (15.94 to 63.31)
24 MonthsNA (NA to NA)30.0 (9.74 to 53.67)
SecondaryDose-Expansion Phase: Cmax of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Reported as:
Geometric mean · mcg/mL
Dose-Expansion Phase: Cmax of Durvalumab
mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Cmax of Durvalumab606 ± 27.7595 ± 14.2
SecondaryDose-Expansion Phase: Cmin of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Reported as:
Geometric mean · mcg/mL
Dose-Expansion Phase: Cmin of Durvalumab
mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Cmin of Durvalumab108 ± 29.678.3 ± 94.1
SecondaryDose-Expansion Phase: AUC (0-14) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Reported as:
Geometric mean · day*mcg/mL
Dose-Expansion Phase: AUC (0-14) of Durvalumab
day*mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-14) of Durvalumab4240 ± 23.23900 ± 20.0
SecondaryDose-Expansion Phase: AUC (0-28) of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Reported as:
Geometric mean · day*mcg/mL
Dose-Expansion Phase: AUC (0-28) of Durvalumab
day*mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-28) of Durvalumab6400 ± 23.75880 ± 25.2
SecondaryDose-Expansion Phase: Tmax of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Reported as:
Median · days
Dose-Expansion Phase: Tmax of Durvalumab
daysSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Tmax of Durvalumab0.049 (0.04 to 0.09)0.051 (0.04 to 0.08)
SecondaryDose-Expansion Phase: T½λz of Durvalumab

Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Reported as:
Geometric mean · days
Dose-Expansion Phase: T½λz of Durvalumab
daysSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: T½λz of Durvalumab17.4 ± 26.214.2 ± 48.6
SecondaryDose-Expansion Phase: AUC (0-14)/D of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Expansion Phase: AUC (0-14)/D of Durvalumab
(day*mcg/mL)/(mg/kg)SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-14)/D of Durvalumab141 ± 23.2130 ± 20.0
SecondaryDose-Expansion Phase: AUC (0-28)/D of Durvalumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Expansion Phase: AUC (0-28)/D of Durvalumab
(day*mcg/mL)/(mg/kg)SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-28)/D of Durvalumab213 ± 23.7196 ± 25.2
SecondaryDose-Expansion Phase: Cmax/D of Durvalumab

Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 8, and 12
Reported as:
Geometric mean · (mcg/mL)/(mg/kg)
Dose-Expansion Phase: Cmax/D of Durvalumab
(mcg/mL)/(mg/kg)SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Cmax/D of Durvalumab20.2 ± 27.719.8 ± 14.2
SecondaryDose-Expansion Phase: Cmax of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Reported as:
Geometric mean · mcg/mL
Dose-Expansion Phase: Cmax of Tremelimumab
mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Cmax of Tremelimumab29.2 ± 86.023.2 ± 18.8
SecondaryDose-Expansion Phase: Cmin of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Cmin was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Reported as:
Geometric mean · mcg/mL
Dose-Expansion Phase: Cmin of Tremelimumab
mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Cmin of Tremelimumab3.91 ± 41.73.40 ± 66.2
SecondaryDose-Expansion Phase: AUC (0-14) of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Reported as:
Geometric mean · day*mcg/mL
Dose-Expansion Phase: AUC (0-14) of Tremelimumab
day*mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-14) of Tremelimumab183 ± 65.9150 ± 11.8
SecondaryDose-Expansion Phase: AUC (0-28) of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-28) was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Reported as:
Geometric mean · day*mcg/mL
Dose-Expansion Phase: AUC (0-28) of Tremelimumab
day*mcg/mLSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-28) of Tremelimumab270 ± 58.1228 ± 12.4
SecondaryDose-Expansion Phase: Tmax of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Tmax was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Reported as:
Median · days
Dose-Expansion Phase: Tmax of Tremelimumab
daysSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Tmax of Tremelimumab0.049 (0.04 to 0.06)0.052 (0.04 to 0.07)
SecondaryDose-Expansion Phase: T½λz of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. T½λz was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Reported as:
Geometric mean · days
Dose-Expansion Phase: T½λz of Tremelimumab
daysSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: T½λz of Tremelimumab15.9 ± 26.215.6 ± 40.4
SecondaryDose-Expansion Phase: AUC (0-14)/D of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-14)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1 and Cycle 1 Day 8
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Expansion Phase: AUC (0-14)/D of Tremelimumab
(day*mcg/mL)/(mg/kg)SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-14)/D of Tremelimumab183 ± 65.9150 ± 11.8
SecondaryDose-Expansion Phase: AUC (0-28)/D of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. AUC (0-28)/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15
Reported as:
Geometric mean · (day*mcg/mL)/(mg/kg)
Dose-Expansion Phase: AUC (0-28)/D of Tremelimumab
(day*mcg/mL)/(mg/kg)SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: AUC (0-28)/D of Tremelimumab270 ± 58.1228 ± 12.4
SecondaryDose-Expansion Phase: Cmax/D of Tremelimumab

Serum samples were collected from the participants at the defined timepoints. Cmax/D was determined using standard non-compartmental methods.

Time frame:
Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 3 Day 1 pre-infusion and post-infusion on Cycle 4
Reported as:
Geometric mean · (mcg/mL)/(mg/kg)
Dose-Expansion Phase: Cmax/D of Tremelimumab
(mcg/mL)/(mg/kg)SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Dose-Expansion Phase: Cmax/D of Tremelimumab29.2 ± 86.023.2 ± 18.8
SecondaryDose-Finding Phase: Percentage of Participants Who Developed Detectable Anti-Drug Antibodies (ADAs)

ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

Time frame:
Pre-infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (durvalumab and tremelimumab), pre-infusion on Cycle 2 Day 1, Cycle 5 Day 1 and Cycle 8 Day 1 for tremelimumab
Reported as:
Number · percentage of participants
Dose-Finding Phase: Percentage of Participants Who Developed Detectable Anti-Drug Antibodies (ADAs)
percentage of participantsArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Durvalumab, ADA positive at any visit25000
Durvalumab, Persistently positive0000
Durvalumab, Transiently positive0000
Tremelimumab, ADA positive at any visit0000
Tremelimumab, Persistently positive0000
Tremelimumab, Transiently positive0000
SecondaryDose-Expansion Phase: Percentage of Participants Who Developed Detectable ADAs

ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. The category includes participants meeting these criteria who are ADA positive at baseline. Transiently positive was defined as having at least 1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category includes participants meeting these criteria who are ADA positive at baseline.

Time frame:
Pre-infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (durvalumab and tremelimumab) and random sample on Cycle 7 Day 1 for tremelimumab
Reported as:
Number · percentage of participants
Dose-Expansion Phase: Percentage of Participants Who Developed Detectable ADAs
percentage of participantsSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Durvalumab, ADA positive at any visit020
Durvalumab, Persistently positive00
Durvalumab, Transiently positive00
Tremelimumab, ADA positive at any visit00
Tremelimumab, Persistently positive00
Tremelimumab, Transiently positive00
SecondaryNumber of Participants With Individual Antibody Titer Measurement

Blood samples were planned to be collected for vaccine antibody titer measurements before and after planned routine immunization.

Time frame:
Pre-infusion on Cycle 1 Day 1 and Cycle 4 Day 1 for durvalumab, pre-infusion on Cycle 1 Day 1, pre-infusion on Cycle 3, 4, and 8 Day 1 for tremelimumab (dose-expansion)
Reported as:
Count of participants · Participants
Number of Participants With Individual Antibody Titer Measurement
ParticipantsArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Number of Participants With Individual Antibody Titer Measurement000000
SecondaryMedian Percent Change From Baseline of Cluster of Differentiation 4+ (CD4+), CD8+, B Cells, Natural Killer (NK) Cells, and T-cell Activation With Ki67

Blood samples were collected at indicated timepoints for flow cytometry assessment. Cycle (C) and Day (D). Data collected for the flow cytometry analysis from the participants enrolled in both the dose finding and dose expansion phase were analyzed in the context of the dosing regimen received, to determine any potential differences in the immune response based on the durvalumab dose.

Time frame:
Pre-dose Cycle 1 Day 8, pre-dose Cycle 2 Day 1, Cycle 2 Day 8, pre-dose Cycle 3 Day 1 (Dose-finding); Pre-dose Cycle 1 Day 1, Cycle 1 Day 8, pre-dose Cycle 2 Day 1 (Dose-expansion)
Reported as:
Median · percentage of cells per cubic millimeter
Median Percent Change From Baseline of Cluster of Differentiation 4+ (CD4+), CD8+, B Cells, Natural Killer (NK) Cells, and T-cell Activation With Ki67
percentage of cells per cubic millimeterDose Expansion: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgDose Finding: Durvalumab 20 mg/kg + Tremelimumab 1mg/kgDose Finding: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
T cells CD4+ Ki67; C1D8112.8 (69.2 to 352.5)——
T cells CD4+ Ki67; C2D110.3 (-45.8 to 57.6)16.7 (-24.0 to 66.7)-25.8 (-43.8 to 37.8)
T cells CD4+ Ki67; C2D8—153.1 (58.0 to 925.0)118.2 (65.1 to 215.0)
T cells CD4+ Ki67; C3D1—-33.4 (-48.0 to -18.8)21.9 (-31.4 to 81.3)
T cells CD8+ Ki67; C1D820.0 (-25.0 to 88.9)——
T cells CD8+ Ki67; C2D1-20.0 (-70.8 to 117.5)133.3 (-9.9 to 431.3)-62.1 (-67.5 to 173.3)
T cells CD8+ Ki67; C2D8—66.7 (-35.2 to 900.0)-40.0 (-57.0 to 318.3)
T cells CD8+ Ki67; C3D1—0.0 (0.0 to 0.0)-55.4 (-73.0 to 200.0)
T cells CD4+; C1D8-12.5 (-20.5 to 2.9)——
T cells CD4+; C2D110.1 (-15.2 to 26.2)6.1 (-20.2 to 45.7)9.2 (-16.6 to 34.9)
T cells CD4+; C2D8—12.8 (-6.5 to 63.8)16.1 (-13.2 to 52.7)
T cells CD4+; C3D1—-12.3 (-32.6 to 8.0)23.0 (6.3 to 39.9)
T cells CD8+; C1D8-23.3 (-37.8 to -10.3)——
T cells CD8+; C2D13.6 (-30.2 to 23.1)40.4 (-18.2 to 59.2)10.6 (-15.6 to 50.6)
T cells CD8+; C2D8—30.1 (-14.6 to 60.9)13.8 (-18.0 to 71.2)
T cells CD8+; C3D1—-8.3 (-24.5 to 7.9)0.6 (-5.5 to 2.6)
B cells; C1D8-29.2 (-40.6 to -24.7)——
B cells; C2D16.2 (-3.1 to 56.9)27.2 (-1.5 to 650.0)-12.0 (-22.0 to 128.0)
B cells; C2D8—20.6 (-4.8 to 1543.8)-8.2 (-26.2 to 43.1)
B cells; C3D1—-2.5 (-8.6 to 3.6)15.7 (-24.4 to 42.1)
NK cells; C1D8-30.1 (-39.7 to 15.2)——
NK cells; C2D1-25.8 (-49.2 to 55.3)31.0 (-1.1 to 59.6)32.2 (14.3 to 56.8)
NK cells; C2D8—7.4 (-28.1 to 75.9)47.4 (22.2 to 55.6)
NK cells; C3D1—25.9 (-9.6 to 61.4)43.7 (-26.9 to 77.2)

Adverse events

Collected over From first dose of study treatment up to approximately 4 years (clinical DCO of 20 Apr 2023). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg6/7 (85.7%)1/7 (14.3%)6/7 (85.7%)
Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg8/11 (72.7%)1/11 (9.1%)11/11 (100%)
Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg3/3 (100%)0/3 (0%)3/3 (100%)
Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg7/8 (87.5%)1/8 (12.5%)7/8 (87.5%)
SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg8/11 (72.7%)6/11 (54.5%)8/11 (72.7%)
STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg7/10 (70%)3/10 (30%)9/10 (90%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
PyrexiaGeneral disorders0/70/110/30/83/110/10
AnaemiaBlood and lymphatic system disorders1/70/110/30/80/110/10
Transverse sinus thrombosisNervous system disorders0/70/110/31/80/110/10
Pulmonary thrombosisRespiratory, thoracic and mediastinal disorders0/70/110/30/80/111/10
ConstipationGastrointestinal disorders0/70/110/30/80/111/10
Platelet count decreasedInvestigations0/70/110/30/80/111/10
LaryngospasmRespiratory, thoracic and mediastinal disorders0/70/110/30/81/110/10
Abdominal painGastrointestinal disorders0/70/110/30/81/110/10
AscitesGastrointestinal disorders0/70/110/30/81/110/10
ColitisGastrointestinal disorders0/71/110/30/80/110/10
Most frequent other events
Showing 10 of 142
Most frequent other events
EventArm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg
Upper respiratory tract infectionInfections and infestations0/70/112/30/81/111/10
NauseaGastrointestinal disorders0/77/110/30/80/111/10
PyrexiaGeneral disorders2/71/110/32/86/114/10
VomitingGastrointestinal disorders3/72/110/33/82/112/10
HeadacheNervous system disorders1/74/110/32/81/112/10
AnaemiaBlood and lymphatic system disorders2/72/111/31/84/113/10
Alanine aminotransferase increasedInvestigations0/74/111/31/82/110/10
PetechiaeSkin and subcutaneous tissue disorders0/70/111/30/80/110/10
DiarrhoeaGastrointestinal disorders0/73/111/30/82/112/10
ContusionInjury, poisoning and procedural complications0/70/111/31/80/110/10

Baseline characteristics

The Full analysis set (FAS) included all participants who were assigned to treatment and received at least 1 dose of study treatment.

Age, Customized
Age, Customized(Participants)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgTotal
In utero0000000
Preterm newborn infants (gestational age < 37 weeks)0000000
Newborns (0-27 days)0000000
Infants and toddlers (28 days-23 months)1000001
Children (2-11 years)05367324
Adolescents (12-17 years)66024725
Adults (18-64 years)0000000
From 65-84 years0000000
85 years and above0000000
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgTotal
Female38136526
Male43255524
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgTotal
Black or African American1101003
Native Hawaiian or other Pacific Islander0000000
American Indian or Alaska Native0000101
Asian0100113
White58248633
Other11131310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kgArm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgSTO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kgTotal
Hispanic or Latino1211027
Not Hispanic or Latino692711843
09

Study locations

19 sites
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    New Hyde Park, New York 11040, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Lille, 59020, France
  • Research Site
    Marseille, 13385, France
  • Research Site
    Paris, 75248, France
  • Research Site
    Cologne, 50924, Germany
  • Research Site
    Genova, 16100, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Rome, 00165, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Utrecht, 3584 CS, Netherlands
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28009, Spain
  • Research Site
    Leeds, LS1 3EX, United Kingdom
  • Research Site
    London, WC1N 3JH, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
10

References and documents

Publications

  • Hargrave D, Marshall LV, Andre N, Krystal J, Ladle BH, Robbins KA, Hois S, Armstrong J, Donegan S. Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. Front Oncol. 2026 May 15;16:1680081. doi: 10.3389/fonc.2026.1680081. eCollection 2026. PubMed 42222420 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Feb 2023, 47 months.

Results were first posted in Mar 2024, 1 year after primary completion.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2019
First posted
Feb 12, 2019
StartActual
Mar 7, 2019
Primary completionActual
Feb 28, 2023
CompletionEst.
Dec 31, 2026
Results first posted
Mar 19, 2024
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT03837899
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Mar 7, 2019
Primary completion
Feb 28, 2023
Completion
Dec 31, 2026 (estimated)
Results posted
Mar 19, 2024
Last update
Sep 29, 2026

Study contacts

Ashok Gupta, MD, PhD
study director · AstraZeneca Global Medicines Development, Academy House

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion